Follow
Raquel Laza Briviesca
Raquel Laza Briviesca
Boston Children´s Hospital-Harvard Medical School
No verified email
Title
Cited by
Cited by
Year
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
5882020
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ...
Free Radical Biology and Medicine 135, 167-181, 2019
1222019
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ...
Free Radical Biology and Medicine 130, 163-173, 2019
962019
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
R Laza‐Briviesca, A Cruz‐Bermúdez, E Nadal, A Insa, ...
Clinical and Translational Medicine 11 (7), e491, 2021
372021
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
M Casarrubios, A Cruz-Bermúdez, E Nadal, A Insa, MR García Campelo, ...
Clinical Cancer Research 27 (21), 5878-5890, 2021
352021
Umbilical cord blood plasma contains soluble NKG2D ligands that mediate loss of natural killer cell function and cytotoxicity
ST Cox, R Laza‐Briviesca, H Pearson, B Soria, D Gibson, S Gomez, ...
European Journal of Immunology 45 (8), 2324-2334, 2015
302015
OA20. 02 pre-treatment levels of ctDNA for long-term survival prediction in stage IIIA NSCLC treated with neoadjuvant chemo-immunotherapy
A Romero, E Nadal, R Serna, A Insa, MRG Campelo, C Benito, M Domine, ...
Journal of Thoracic Oncology 16 (10), S883-S884, 2021
242021
PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy
A Cruz-Bermúdez, RJ Vicente-Blanco, R Laza-Briviesca, ...
Scientific Reports 7 (1), 16661, 2017
242017
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
A Romero, R Serna-Blasco, C Alfaro, E Sánchez-Herrero, M Barquín, ...
Translational Lung Cancer Research 9 (3), 532, 2020
182020
Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model
M Escobedo-Cousin, N Jackson, R Laza-Briviesca, L Ariza-McNaughton, ...
PLoS One 10 (10), e0138623, 2015
172015
Next-generation sequencing for tumor mutation quantification using liquid biopsies
M Provencio, C Pérez-Barrios, M Barquin, V Calvo, F Franco, E Sánchez, ...
Clinical Chemistry and Laboratory Medicine (CCLM) 58 (2), 306-313, 2020
142020
OA20. 01 long term survival in operable stage Iiia Nsclc patients treated with neoadjuvant nivolumab plus chemotherapy-nadim study
M Provencio, E Nadal, A Insa, MRG Campelo, D Pereiro, M Domine, ...
Journal of Thoracic Oncology 16 (10), S883, 2021
132021
Functional characterisation and analysis of the soluble NKG2D ligand repertoire detected in umbilical cord blood plasma
ST Cox, R Danby, D Hernandez, R Laza-Briviesca, H Pearson, ...
Frontiers in immunology 9, 353246, 2018
132018
Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy, and chemoimmunotherapy in resectable NSCLC
P Rocha, J Zhang, R Laza-Briviesca, A Cruz-Bermúdez, ...
Clinical Cancer Research 28 (11), 2461-2473, 2022
102022
The role of metabolism in tumor immune evasion: novel approaches to improve immunotherapy
A Cruz-Bermúdez, R Laza-Briviesca, M Casarrubios, B Sierra-Rodero, ...
Biomedicines 9 (4), 361, 2021
82021
P2. 04-10 biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
R Laza-Briviesca, A Cruz-Bermudez, M Casarrubios, E Nadal, A Insa, ...
Journal of Thoracic Oncology 14 (10), S711, 2019
72019
Characterization of 5′ promoter and exon 1–3 polymorphism of the RAET1E gene
ST Cox, H Pearson, R Laza-Briviesca, S Pesoa, C Vullo, JA Madrigal, ...
Human Immunology 77 (1), 96-103, 2016
72016
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
B Sierra-Rodero, A Cruz-Bermúdez, E Nadal, Y Garitaonaindía, A Insa, ...
Journal for immunotherapy of cancer 9 (8), 2021
62021
KRAS p. G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
R Serna-Blasco, E Sánchez-Herrero, S Sanz-Moreno, A Rodriguez-Festa, ...
ESMO open 6 (5), 100279, 2021
52021
Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy …
A Cruz Bermudez, M Casarrubios, R Laza Briviesca, B Sierra-Rodero, ...
Journal of Clinical Oncology 38 (15_suppl), 9041-9041, 2020
42020
The system can't perform the operation now. Try again later.
Articles 1–20